We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dynavax Technologies (DVAX) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Dynavax Technologies (DVAX - Free Report) closed at $14.07 in the latest trading session, marking a -1.05% move from the prior day. This change lagged the S&P 500's 0.26% loss on the day. At the same time, the Dow lost 0.16%, and the tech-heavy Nasdaq lost 0.04%.
Prior to today's trading, shares of the biopharmaceutical company had lost 3.27% over the past month. This has lagged the Medical sector's gain of 5.77% and the S&P 500's gain of 4.82% in that time.
Dynavax Technologies will be looking to display strength as it nears its next earnings release. In that report, analysts expect Dynavax Technologies to post earnings of $0.69 per share. This would mark year-over-year growth of 592.86%. Meanwhile, our latest consensus estimate is calling for revenue of $229.07 million, up 1071.71% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.50 per share and revenue of $473.44 million. These totals would mark changes of +181.97% and +917.04%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Dynavax Technologies. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 9.24% higher within the past month. Dynavax Technologies is currently sporting a Zacks Rank of #2 (Buy).
Digging into valuation, Dynavax Technologies currently has a Forward P/E ratio of 28.44. This represents a premium compared to its industry's average Forward P/E of 23.35.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 162, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DVAX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Dynavax Technologies (DVAX) Dips More Than Broader Markets: What You Should Know
Dynavax Technologies (DVAX - Free Report) closed at $14.07 in the latest trading session, marking a -1.05% move from the prior day. This change lagged the S&P 500's 0.26% loss on the day. At the same time, the Dow lost 0.16%, and the tech-heavy Nasdaq lost 0.04%.
Prior to today's trading, shares of the biopharmaceutical company had lost 3.27% over the past month. This has lagged the Medical sector's gain of 5.77% and the S&P 500's gain of 4.82% in that time.
Dynavax Technologies will be looking to display strength as it nears its next earnings release. In that report, analysts expect Dynavax Technologies to post earnings of $0.69 per share. This would mark year-over-year growth of 592.86%. Meanwhile, our latest consensus estimate is calling for revenue of $229.07 million, up 1071.71% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.50 per share and revenue of $473.44 million. These totals would mark changes of +181.97% and +917.04%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Dynavax Technologies. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 9.24% higher within the past month. Dynavax Technologies is currently sporting a Zacks Rank of #2 (Buy).
Digging into valuation, Dynavax Technologies currently has a Forward P/E ratio of 28.44. This represents a premium compared to its industry's average Forward P/E of 23.35.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 162, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DVAX in the coming trading sessions, be sure to utilize Zacks.com.